Show simple item record

dc.contributor.authorGurwitz, Jerry H.
dc.contributor.authorBohn, Rhonda L.
dc.contributor.authorGlynn, Robert J.
dc.contributor.authorMonane, Mark
dc.contributor.authorMogun, Helen
dc.contributor.authorAvorn, Jerry
dc.date2022-08-11T08:09:21.000
dc.date.accessioned2022-08-23T16:27:30Z
dc.date.available2022-08-23T16:27:30Z
dc.date.issued1994-01-10
dc.date.submitted2009-09-29
dc.identifier.citationArch Intern Med. 1994 Jan 10;154(1):97-101.
dc.identifier.issn0003-9926
dc.identifier.pmid8267494
dc.identifier.pmid8267494
dc.identifier.urihttp://hdl.handle.net/20.500.14038/36800
dc.description.abstractPURPOSE: To quantify risk for the occurrence of hyperglycemia requiring initiation of hypoglycemic therapy in patients treated with oral glucocorticoids. PATIENTS AND METHODS: A case-control study of enrollees in the New Jersey Medicaid program 35 years of age or older. The 11,855 case patients had newly initiated treatment with a hypoglycemic agent (oral or insulin) between 1981 and 1990. The 11,855 controls represented a random sample of other Medicaid enrollees. RESULTS: In patients using oral glucocorticoids, the estimated relative risk for development of hyperglycemia requiring treatment was 2.23 (95% confidence interval, 1.92 to 2.59) as compared with nonusers. Risk increased with increasing average daily steroid dose, in hydrocortisone-equivalent milligrams; the odds ratio was 1.77 for 1 to 39 mg/d, 3.02 for 40 to 79 mg/d, 5.82 for 80 to 119 mg/d, and 10.34 for 120 mg/d or more. The estimated effects persisted after adjustment for a variety of potentially confounding demographic, health service utilization, and medication use variables. CONCLUSION: The findings of this population-based study quantify the risk of developing hyperglycemia requiring hypoglycemic therapy after oral glucocorticoid use. The magnitude of risk increases substantially with increasing glucocorticoid dose. These findings demonstrate the utility of large-scale health claims databases in defining the risk of important adverse drug effects.
dc.language.isoen_US
dc.publisherAmerican Medical Association
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8267494&dopt=Abstract">Link to article in PubMed</a>
dc.relation.urlhttp://archinte.ama-assn.org/cgi/reprint/154/1/97
dc.subjectAdministration, Oral
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectCase-Control Studies
dc.subjectFemale
dc.subjectGlucocorticoids
dc.subjectHumans
dc.subjectHypoglycemia
dc.subjectMale
dc.subjectMedicaid
dc.subjectMiddle Aged
dc.subjectNew Jersey
dc.subjectRisk
dc.subjectStatistics as Topic
dc.subjectUnited States
dc.subjectHealth Services Research
dc.subjectMedicine and Health Sciences
dc.titleGlucocorticoids and the risk for initiation of hypoglycemic therapy.
dc.typeJournal Article
dc.source.journaltitleArchives of internal medicine
dc.source.volume154
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/meyers_pp/161
dc.identifier.contextkey1019654
html.description.abstract<p>PURPOSE: To quantify risk for the occurrence of hyperglycemia requiring initiation of hypoglycemic therapy in patients treated with oral glucocorticoids. PATIENTS AND METHODS: A case-control study of enrollees in the New Jersey Medicaid program 35 years of age or older. The 11,855 case patients had newly initiated treatment with a hypoglycemic agent (oral or insulin) between 1981 and 1990. The 11,855 controls represented a random sample of other Medicaid enrollees. RESULTS: In patients using oral glucocorticoids, the estimated relative risk for development of hyperglycemia requiring treatment was 2.23 (95% confidence interval, 1.92 to 2.59) as compared with nonusers. Risk increased with increasing average daily steroid dose, in hydrocortisone-equivalent milligrams; the odds ratio was 1.77 for 1 to 39 mg/d, 3.02 for 40 to 79 mg/d, 5.82 for 80 to 119 mg/d, and 10.34 for 120 mg/d or more. The estimated effects persisted after adjustment for a variety of potentially confounding demographic, health service utilization, and medication use variables. CONCLUSION: The findings of this population-based study quantify the risk of developing hyperglycemia requiring hypoglycemic therapy after oral glucocorticoid use. The magnitude of risk increases substantially with increasing glucocorticoid dose. These findings demonstrate the utility of large-scale health claims databases in defining the risk of important adverse drug effects.</p>
dc.identifier.submissionpathmeyers_pp/161
dc.contributor.departmentDepartment of Medicine, Division of Geriatric Medicine
dc.contributor.departmentMeyers Primary Care Institute


This item appears in the following Collection(s)

Show simple item record